Latest Advancements in Auto Injector Technology

Over the last decade, the drug delivery systems market has witnessed a steady influx of novel delivery devices and emerged as one of the most promising segments of the pharmaceutical industry. Ongoing innovation and extensive research efforts in this domain have led to the development and commercialization of several novel self-injection devices.

Self-injection devices, such as autoinjectors, enable delivery of therapeutics in homecare settings, and are convenient and easy to use. The autoinjectors are spring-loaded syringes working on various mechanisms (ranging from simple push-on-skin devices to fully automated button activated technologies) and include pre-measured medication, which eliminates the need to draw medication from a separate vial, thus resolving various injection-related compliance issues faced by the patients. Further, the audio-visual features in some of the autoinjectors allow the patients to remove the device from the skin when the dose is completed. These devices enable the administration of injectables through different routes of administration in an efficient and relatively simple manner.

With the growing adoption of self-administration devices and ongoing advancements in the technologies (focused on integrated needle safety, Bluetooth connectivity and monitoring of historical injection logs), the global autoinjectors market is likely to grow, in the foreseen future.

Roots Analysis has conducted an exhaustive study on Autoinjectors Market featuring the current market landscape and future opportunity for the companies engaged in developing autoinjectors, over a span of 11 years. In this article, we have highlighted some of the latest advancements in the auto injector technology that are likely to shape the evolution of autoinjectors market.

Want to explore the latest advancements in auto injector technology??

LATEST ADVANCEMENTS IN AUTO INJECTOR TECHNOLOGY THAT ARE LIKELY TO SHAPE THE AUTOINJECTORS MARKET

1.  CONNECTED AUTOINJECTORS: REVOLUTIONIZING THE HEALTHCARE INDUSTRY

Connected autoinjectors facilitate real-time monitoring, rendering them appropriate for remote clinical trials. These autoinjectors track the medication usage and provide reminders to the patients, improving adherence to the treatment regimens and enhancing the therapeutic outcomes. Phillips-Medisize was amongst the first companies to launch a connected autoinjector Aria in 2021.

2.  SURGE IN THE APPROVALS FOR AUTOINJECTOR COMBINATION PRODUCTS

In recent years, there has been a notable increase in the number of commercialized autoinjector drug device combination products for the treatment of a wide array of indications. This surge reflects the industry's ability to respond to the evolving needs of patients and healthcare providers, while navigating the complex regulatory environment. In July 2024, Fresenius Kabi launched subcutaneous formulation of its tocilizumab biosimilar, Tyenne in the US. The drug is available in a prefilled syringe and an autoinjector.

3.  PIONEERING GROWTH: GLP-1 DRUGS SPEARHEAD THE AUTOINJECTOR REVOLUTION

Foreseeing the potential of autoinjectors in delivering drugs suitable for treatment of weight loss, the domain has witnessed significant agreements and investments for the development of autoinjectors in large quantities; examples of key investors include Eli Lilly and Company and Novo Nordisk. GLP-1 drugs, which are approved for obesity and diabetes require the patients to take daily or weekly injections. As such, the demand for GLP-1 will drive the market for autoinjectors. In 2023, Novo Nordisk signed a long-term supply agreement with Ypsomed for delivery of autoinjectors for its GLP-1 drugs.

4.  ONGOING EFFORTS: ESTABLISHING A ROBUST REGULATORY FRAMEWORK

Regulatory bodies and industry stakeholders are actively engaged in the development of comprehensive and streamlined regulatory framework for autoinjectors. The initiative focuses to bridge existing gaps by proposing a comprehensive Medical Device Development Tool (MDDT) framework tailored specifically for autoinjectors, ultimately expediting regulatory approval processes and enhancing the quality and safety of these combination products.

5.  RISING DEMAND FOR ADVANCED DRUG DELIVERY SYSTEMS FOR NOVEL BIOLOGICS

The growth of the autoinjector market has been significantly fueled by the rising need for novel biologics and biosimilars, which require more efficient drug delivery systems. Stakeholders are eager to seize this growth potential by investing in autoinjectors to fulfill market requirements. The ability to brand and patent the combination of a drug with autoinjectors, provides manufacturers a competitive advantage and protects their innovative products.

6.  AUTOINJECTORS EMBRACING SUSTAINABILITY: A PATH TO GREENER HEALTHCARE SOLUTIONS

Autoinjectors have made significant strides in addressing sustainability through innovative approaches. The utilization of eco-friendly materials, such as bio-based styrene acrylic copolymer in autoinjector housing has resulted in significant reduction in carbon footprint. Additionally, autoinjectors integrate reusable components, sustainable design elements, and comprehensive lifecycle assessments to minimize environmental impact and promote environmentally conscious healthcare solutions.

7.  EXPANDING HORIZONS: CARTRIDGE-BASED AUTOINJECTORS BREAK THE 2 ML BARRIER

Cartridge-based autoinjectors have emerged as a promising solution for the delivery of complex and sensitive molecules and can accommodate higher volumes without compromising the drug’s integrity. The autoinjectors feature appropriate material composition, eliminating components including tungsten that may interact with / degrade sensitive biologics, minimizing the risk of unwanted interactions that could compromise the stability and efficacy of the drug product.

CONCLUSION

The 7 latest advancements in auto injector technology are in line with the growing trends towards self-administration. Over the years, autoinjectors have demonstrated significant potential as the next generation of patient-centric devices, capable of safe and reliable delivery of injectables. The growing awareness among patient groups across the globe has encouraged them to adopt autoinjectors over exposed needles and prefilled syringes. Further, the advent of novel biologics is driving the demand for injection of higher viscosities of drugs in larger volumes. Consequently, many device manufacturers, such as BD Medical and SHL, have introduced large volume autoinjectors.

Given the increasing demand for drug delivery devices, there is a need within the pharmaceutical industry to provide customization and additional enhancements in their devices for product differentiation. This has led the device manufacturers to incorporate feedback features in their systems, that allow them to gain insights from injection therapy users for designing new and updated versions of autoinjectors with advanced features.

It is worth noting that the new autoinjector devices, which are currently under development, are capable of addressing the specific needs and wants of individual patients. These are designed to enable adjustments in the dosage or features of the device based upon the requirements of the user. Further, connecting the injectors digitally to various products and platforms is expected to improve adherence and quality of life for the patients. Such connected combination products are aimed at combining information for all therapies and lifestyle of the patients to improve the healthcare outcomes.

Considering the rise in needlestick injuries, along with fast-paced innovation in drug delivery devices, the demand for self-injecting devices, such as autoinjectors, is likely to increase in the foreseen future.

Browse our full report on Autoinjectors Market:
https://www.rootsanalysis.com/reports/autoinjectors-market/293.html#overview